Press Releases - Ipsen UK
FOP Fnd NL on X: "Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies ...for children under the age of 14 because of some cases with early growth plate closure...
Press Releases - Ipsen UK
Ipsen media library
IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter
Paul van Doesburg, CEO, Ipsen, Germany | The Monty
Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief | Business Wire
Press Releases - Ipsen UK
Mayoly Spindler completed the acquisition of Ipsen's CHC branch - MAYOLY SPINDLER laboratoire indépendant français
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts | Financial Post
Ipsen ships 18 furnaces in Q2, including 210,000-pound capacity vacuum furnace | ASM International
LeaveRussia: Ipsen is Pausing New Investments in Russia
Gebrüder Weiss takes over Ipsen Logistics' Air & Sea business | DC Velocity
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire
Press Releases - Ipsen UK
Press Releases - Ipsen UK
Emirates Oncology Society And Ipsen Break Guinness World Record For Largest Awareness Ribbon | Press Release Network
Ipsen is officially recognized as a great place to work worldwide - Global
Ipsen puts patients first
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides | BioSpace
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group
Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation - Global
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
